AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients
AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients, Integrating the Complete Care Pathway and an Interoperable Clinical Interface With Algorithms Paired With Explainability Tools.
This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 210 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Grand Hôpital de Charleroi Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Charleroi, Hainaut) |
| Trial ID | NCT07546188 on ClinicalTrials.gov |
What this trial studies
The project uses retrospective and prospective patient data from the Haematology Department to train and test machine learning models that predict non-adherence to oral therapies. It combines clinical variables, dispensing history, lab results, and drug interaction data with supervised algorithms and neural networks to identify patients at risk. The system will produce real-time alerts and tailored recommendations for physicians and coordinating nurses, supported by an intuitive interface that shows adherence trends. A multidisciplinary team including hematologists, advanced practice nurses, data scientists and patient partners will validate the tool in routine care.
Who should consider this trial
Good fit: Adults (18+) treated for Non-Hodgkin lymphoma in the Haematology Department at Grand Hôpital de Charleroi from November 2025 onward who can give informed consent are eligible.
Not a fit: Patients not treated at the center, those not taking oral prophylactic or targeted therapies, or those without sufficient clinical/dispensing data or capacity to consent are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the tool could reduce missed doses, lower the risk of treatment failure and severe infections, and shorten hospital stays by triggering timely, targeted support.
How similar studies have performed: Digital adherence programs in other chronic conditions have shown encouraging but mixed results, while AI-driven, real-world predictive tools for oral oncology adherence remain relatively novel and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards * Treated for a lymphoma, Non Hodgkin * Capable of giving informed consent Exclusion Criteria: * All other patients who did not meet the eligibility criteria
Where this trial is running
Charleroi, Hainaut
- Grand Hôpital de Charleroi — Charleroi, Hainaut, Belgium (Recruiting)
Study contacts
- Principal investigator: Marie Detrait, MD, PhD — Grand Hôpital de Charleroi
- Study coordinator: Marie Detrait, MD, PhD
- Email: marie.detrait@ghdc.be
- Phone: 0032 60 11 20 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.